TBK1 inhibitors as novel therapeutics for rheumatoid arthritis

TBK1抑制剂作为类风湿性关节炎的新疗法

• 批准号: nhmrc : 1055374
• 负责人: A/Pr Christopher Burns
• 金额: $ 34.12万
• 依托单位: The Walter and Eliza Hall Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Development Grants
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/tbk1-inhibitors-novel-rheumatoid-arthritis/112455
• 关键词: TBK1; inhibitors; novel; therapeutics; rheumatoid

A key feature of rheumatoid arthritis is inflammation in affected joints causing pain and immobility. New drugs that selectively block processes that are dysregulated in rheumatoid arthritis are needed to better treat this disease. The protein called TBK1 is a key regulator of inflammation and we aim to develop drugs that inhibit TBK1 activity thereby blocking the inflammation and symptoms associated with rheumatoid arthritis.

类风湿性关节炎的一个关键特征是受影响关节的炎症，引起疼痛和不动。需要选择性阻断类风湿性关节炎中失调过程的新药来更好地治疗这种疾病。TBK1蛋白是炎症的关键调节因子，我们的目标是开发抑制TBK1活性的药物，从而阻断与类风湿性关节炎相关的炎症和症状。